Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Table of Contents
01_Pre-Meeting Briefing
02_Company submission from Roche Products
03_NICE request to the company for clarification on their submission
04_Company response to NICE's request for clarification
05_Consultee submission- Chronic Lymphocytic Leukaemia Support Association
06_Consultee submission- Lymphoma Association
07_Consultee submission- Joint Submission Royal College of Pathologists and British Society for Haematology
08_Consultee submission- Royal College of Physicians
09_Clinical expert personal perspective- CDearden
10_Patient expert personal perspective- JWilson
11_Evidence Review Group report prepared by Peninsula Technology Assessment Group (PenTAG)
12_Erratum to the Evidence Review Group report prepared by Peninsula Technology Assessment Group (PenTAG)
13_Company factual accuracy check of Evidence Review Group report
14_Evidence Review Group response to factual accuracy check
Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: evaluation report
03 October 2014 (10.83 Mb 50 sec) |
This page was last updated: 30 September 2014